Wide Ranks

DTIL

Precision BioSciences, Inc.

7.11

Top Statistics
Market Cap 54 M Forward PE -0.8248 Revenue Growth -95.60 %
Current Ratio 9.22 Trailing PE 17.77 Earnings Growth 0.00 %
Profit Margins 11.48 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 1.36 Enterprise / Revenue -0.2180 Price To Sales Trailing12 Months 0.7263
Profitability
Profit Margins 11.48 % Operating Margins -3693.58 %
Balance Sheet
Total Cash 101 M Total Cash Per Share 13.19 Total Debt 30 M
Total Debt To Equity 46.72 Current Ratio 9.22 Book Value Per Share 8.67
All Measures
Short Ratio 253.00 % Message Board Id finmb_41018856 Fax 480 393 5553
Shares Short Prior Month 214461 Return On Equity 0.2444 City Durham
Uuid 3c610058-9f43-33c6-b360-7e8a0bce4509 Previous Close 6.86 First Trade Date Epoch Utc 1 B
Book Value 8.67 Beta 1.69 Total Debt 30 M
Volume 77246 Price To Book 0.8200 Last Split Date 1 B
Fifty Two Week Low 6.41 Total Cash Per Share 13.19 Total Revenue 75 M
Shares Short Previous Month Date 1 B Target Median Price 32.00 Max Age 86400
Recommendation Mean 1.60 Sand P52 Week Change 0.3133 Operating Margins -3693.58 %
Target Mean Price 35.75 Net Income To Common 11 M Short Percent Of Float 0.0317
Implied Shares Outstanding 7 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 101420 Average Volume10days 101420 Total Cash 101 M
Next Fiscal Year End 1 B Revenue Per Share 12.87 Held Percent Insiders 0.0658
Ebitda Margins -15.95 % Trailing PE 17.77 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 6.86 Target Low Price 19.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 8.49 Open 6.86
Free Cashflow 4 M State NC Dividend Yield 0.00 %
Return On Assets -0.0638 Time Zone Short Name EST Trailing Eps 0.4000
Day Low 6.76 Address1 302 East Pettigrew Street Shares Outstanding 7 M
Price Hint 2 Target High Price 60.00 Website https://www.precisionbiosciences.com
52 Week Change -0.3324 Average Volume 77721 Forward Eps -6.78
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 857.50 %
Last Split Factor 1:30 Regular Market Day High 7.17 Is_sp_500 False
Profit Margins 11.48 % Debt To Equity 46.72 Fifty Two Week High 19.43
Day High 7.17 Shares Short 239855 Regular Market Open 6.86
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue -0.2180
Revenue Growth -95.60 % Shares Percent Shares Out 0.0313 Operating Cashflow -48185000
Currency USD Time Zone Full Name America/New_York Market Cap 54 M
Is_nasdaq_100 False Zip 27701 Quote Type EQUITY
Industry Biotechnology Long Name Precision BioSciences, Inc. Regular Market Day Low 6.76
Held Percent Institutions 0.4470 Current Price 7.11 Address2 Suite A-100
Enterprise To Ebitda 1.36 Financial Currency USD Current Ratio 9.22
Gross Margins 100.00 % Industry Disp Biotechnology Number Of Analyst Opinions 4
Country United States Float Shares 6 M Two Hundred Day Average 10.53
Enterprise Value -16353771 Price To Sales Trailing12 Months 0.7263 Forward PE -0.8248
Regular Market Volume 77246 Ebitda -11977000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States.

The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair.

It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.

3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.

In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency.

The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.

A.

; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products.

Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.